Human Direct Skin Feeding Versus Membrane Feeding to Assess the Mosquitocidal Efficacy of High-Dose Ivermectin (IVERMAL Trial)

BACKGROUND

Ivermectin is being considered for mass drug administration for malaria, due to its ability to kill mosquitoes feeding on recently treated individuals. In a recent trial, 3-day courses of 300 and 600 mcg/kg/day were shown to kill Anopheles mosquitoes for at least 28 days post-treatment when fed patients' venous blood using membrane feeding assays. Direct skin feeding on humans may lead to higher mosquito mortality, as ivermectin capillary concentrations are higher. We compared mosquito mortality following direct skin and membrane feeding.

METHODS

We conducted a mosquito feeding study, nested within a randomized, double-blind, placebo-controlled trial of 141 adults with uncomplicated malaria in Kenya, comparing 3 days of ivermectin 300 mcg/kg/day, ivermectin 600 mcg/kg/day, or placebo, all co-administered with 3 days of dihydroartemisinin-piperaquine. On post-treatment day 7, direct skin and membrane feeding assays were conducted using laboratory-reared Anopheles gambiae sensu stricto. Mosquito survival was assessed daily for 28 days post-feeding.

RESULTS

Between July 20, 2015, and May 7, 2016, 69 of 141 patients participated in both direct skin and membrane feeding (placebo, n = 23; 300 mcg/kg/day, n = 24; 600 mcg/kg/day, n = 22). The 14-day post-feeding mortality for mosquitoes fed 7 days post-treatment on blood from pooled patients in both ivermectin arms was similar with direct skin feeding (mosquitoes observed, n = 2941) versus membrane feeding (mosquitoes observed, n = 7380): cumulative mortality (risk ratio 0.99, 95% confidence interval [CI] 0.95-1.03, P = .69) and survival time (hazard ratio 0.96, 95% CI 0.91-1.02, P = .19). Results were consistent by sex, by body mass index, and across the range of ivermectin capillary concentrations studied (0.72-73.9 ng/mL).

CONCLUSIONS

Direct skin feeding and membrane feeding on day 7 resulted in similar mosquitocidal effects of ivermectin across a wide range of drug concentrations, suggesting that the mosquitocidal effects seen with membrane feeding accurately reflect those of natural biting. Membrane feeding, which is more patient friendly and ethically acceptable, can likely reliably be used to assess ivermectin's mosquitocidal efficacy.

CLINICAL TRIALS REGISTRATION

NCT02511353.

Pharmacokinetics-Pharmacodynamics of High-Dose Ivermectin with Dihydroartemisinin-Piperaquine on Mosquitocidal Activity and QT-Prolongation (IVERMAL)

High‐dose ivermectin, co‐administered for 3 days with dihydroartemisinin‐piperaquine (DP), killed mosquitoes feeding on individuals for at least 28 days posttreatment in a recent trial (IVERMAL), whereas 7 days was predicted pretrial. The current study assessed the relationship between ivermectin blood concentrations and the observed mosquitocidal effects against Anopheles gambiae s.s. Three days of ivermectin 0, 300, or 600 mcg/kg/day plus DP was randomly assigned to 141 adults with uncomplicated malaria in Kenya. During 28 days of follow‐up, 1,393 venous and 335 paired capillary plasma samples, 850 mosquito‐cluster mortality rates, and 524 QTcF‐intervals were collected. Using pharmacokinetic/pharmacodynamic (PK/PD) modeling, we show a consistent correlation between predicted ivermectin concentrations and observed mosquitocidal‐effects throughout the 28‐day study duration, without invoking an unidentified mosquitocidal metabolite or drug‐drug interaction. Ivermectin had no effect on piperaquine's PKs or QTcF‐prolongation. The PK/PD model can be used to design new treatment regimens with predicted mosquitocidal effect. This methodology could be used to evaluate effectiveness of other endectocides.

Safety and mosquitocidal efficacy of high-dose ivermectin when co-administered with dihydroartemisinin-piperaquine in Kenyan adults with uncomplicated malaria (IVERMAL): a randomised, double-blind, placebo-controlled trial

BACKGROUND

Ivermectin is being considered for mass drug administration for malaria due to its ability to kill mosquitoes feeding on recently treated individuals. However, standard, single doses of 150-200 μg/kg used for onchocerciasis and lymphatic filariasis have a short-lived mosquitocidal effect (<7 days). Because ivermectin is well tolerated up to 2000 μg/kg, we aimed to establish the safety, tolerability, and mosquitocidal efficacy of 3 day courses of high-dose ivermectin, co-administered with a standard malaria treatment.

METHODS

We did a randomised, double-blind, placebo-controlled, superiority trial at the Jaramogi Oginga Odinga Teaching and Referral Hospital (Kisumu, Kenya). Adults (aged 18-50 years) were eligible if they had confirmed symptomatic uncomplicated Plasmodium falciparum malaria and agreed to the follow-up schedule. Participants were randomly assigned (1:1:1) using sealed envelopes, stratified by sex and body-mass index (men: <21 vs ≥21 kg/m²; women: <23 vs ≥23 kg/m²), with permuted blocks of three, to receive 3 days of ivermectin 300 μg/kg per day, ivermectin 600 μg/kg per day, or placebo, all co-administered with 3 days of dihydroartemisinin-piperaquine. Blood of patients taken on post-treatment days 0, 2 + 4 h, 7, 10, 14, 21, and 28 was fed to laboratory-reared Anopheles gambiae sensu stricto mosquitoes, and mosquito survival was assessed daily for 28 days after feeding. The primary outcome was 14-day cumulative mortality of mosquitoes fed 7 days after ivermectin treatment (from participants who received at least one dose of study medication). The study is registered with ClinicalTrials.gov, number NCT02511353.

FINDINGS

Between July 20, 2015, and May 7, 2016, 741 adults with malaria were assessed for eligibility, of whom 141 were randomly assigned to receive ivermectin 600 μg/kg per day (n=47), ivermectin 300 μg/kg per day (n=48), or placebo (n=46). 128 patients (91%) attended the primary outcome visit 7 days post treatment. Compared with placebo, ivermectin was associated with higher 14 day post-feeding mosquito mortality when fed on blood taken 7 days post treatment (ivermectin 600 μg/kg per day risk ratio [RR] 2·26, 95% CI 1·93-2·65, p<0·0001; hazard ratio [HR] 6·32, 4·61-8·67, p<0·0001; ivermectin 300 μg/kg per day RR 2·18, 1·86-2·57, p<0·0001; HR 4·21, 3·06-5·79, p<0·0001). Mosquito mortality remained significantly increased 28 days post treatment (ivermectin 600 μg/kg per day RR 1·23, 1·01-1·50, p=0·0374; and ivermectin 300 μg/kg per day 1·21, 1·01-1·44, p=0·0337). Five (11%) of 45 patients receiving ivermectin 600 μg/kg per day, two (4%) of 48 patients receiving ivermectin 300 μg/kg per day, and none of 46 patients receiving placebo had one or more treatment-related adverse events.

INTERPRETATION

Ivermectin at both doses assessed was well tolerated and reduced mosquito survival for at least 28 days after treatment. Ivermectin 300 μg/kg per day for 3 days provided a good balance between efficacy and tolerability, and this drug shows promise as a potential new tool for malaria elimination.

FUNDING

Malaria Eradication Scientific Alliance (MESA) and US Centers for Disease Control and Prevention (CDC).

Detection of avian influenza viruses in wild waterbirds in the Rift Valley of Kenya using fecal sampling

Highly pathogenic avian influenza virus A/H5N1 has been reported in 11 African countries. Migratory waterbirds have the potential of introducing A/H5N1 into east Africa through the Rift Valley of Kenya. We present the results of a wild bird surveillance system for A/H5N1 and other avian influenza viruses based on avian fecal sampling in Kenya. We collected 2630 fecal samples in 2008. Viral RNA was extracted from pools of 3-5 fecal samples and analyzed for presence of avian influenza virus RNA by real-time RT-PCR. Twelve (2.3%) of the 516 sample pools were positive for avian influenza virus RNA, 2 of which were subtyped as H4N6 viruses. This is the first report of avian influenza virus in wild birds in Kenya. This study demonstrates the success of this approach in detecting avian influenza virus in wild birds and represents an efficient surveillance system for avian influenza virus in regions with limited resources.

Factors contributing to antimalarial drug resistance in Rachuonyo district, Kenya

Drug resistance has been identified as one of the factors that lead to severe malaria and high mortality as observed in malaria endemic areas. The main objective of this study was to establish the factors that contribute to essential drug resistance in the treatment of malaria in Rachuonyo District, Kenya. Qualitative and quantitative data were collected among 380 respondents including health care providers, people seeking malaria treatment and Community Own Resource (CORPs), from 47 registered health facilities. The study revealed that all health facilities were using general-purpose trucks to transport antimalarial drugs and did not have functional wall thermometers and that eighty seven per cent (87%) of health care providers did not check storage conditions of drugs upon reception. Ninety seven per cent (97%) of the health care providers used physical examination for clinical diagnoses that is subject to errors that may lead to irrational drug use. Thirteen per cent (13%) of health care providers had no idea that antimalarials suspensions can undergo fermentation when not properly stored. Forty percent (40%) of the selected health facilities had current recommended antimalarial treatment drugs in stock. The use of such vehicles can affect the potency of the drugs, as they do not have the necessary equipments to control adverse temperatures and this may contribute to loss of potency. Some health facilities did not have the current recommended antimalarial drugs in stock implying that patients attending treatment in these facilities could have been treated with less effective drugs or they could have been sent to purchase them yet they are expensive and not easily available. In conclusion the results of this study indicate that management, administrative factors and policy issues could be a leading cause of antimalarial drug resistance and a case control study to explore the exact extent of drug resistance in this population in relation to the identified factors is urgently recommended.

Prevalence of Escherichia coli O157:H7 among diarrhoeic HIV/AIDS patients in the Eastern Cape Province-South Africa

This study investigated the prevalence of Escherichia coli O157:H7 in the stool of confirmed and non-confirmed diarrhoeic HIV/AIDS patients. Escherichia coli O157:H7 was isolated by culture-based and immunomagnetic separation from three hundred and sixty stool swabs. Identification was by conventional IMViC, 20E API and molecular techniques. Confirmed and non-confirmed diarrhoeic HIV/AIDS patients had 56.5% (74/131) and 43.5% (57/131) respectively of E. coli O157:H7. Molecular results indicated that the prevalence of E. coli O157:H7 was 12.16% (9/74) and 8.77% (5/57) from stool swabs of confirmed and non-confirmed diarrhoeic HIV/AIDS patients. Antimicrobial resistance was higher for E. coli O157:H7 isolates from stools of confirmed HIV/AIDS than it was for non-confirmed HIV/AIDS patients. Escherichia coli O157:H7 might be a silent cause of diarrhoea in HIV/AIDS patients. It is recommended that HIV/AIDS patients with diarrhoea should be screened for E. coli O157:H7 and surveillance programmes for these bacteria should be established in both urban and rural areas of South Africa.

Prevalence and antimicrobial susceptibility of Escherichia coli O157:H7 in vegetables sold in the Amathole District, Eastern Cape Province of South Africa

Fresh vegetables have been implicated in outbreaks of Escherichia coli O157:H7 in most parts of the world. Microbiological quality of vegetables used as recipes for salads is very crucial. Residents of the Amathole District in the Eastern Cape Province of South Africa consume salads frequently, although the microbial quality of recipe vegetables is questionable. The present study investigated the prevalence and antimicrobial susceptibility of E. coli O157:H7 isolated from selected vegetables sold within the Amathole District. One hundred eighty samples of the vegetables were analyzed. Strains of E. coli O157:H7 were isolated by enrichment culture and by immunomagnetic separation and identified by conventional and molecular techniques. In three settlements in this district, the mean counts of presumptive E. coli O157 for the vegetables ranged between 9 x 10(3) and 1.6 x 10(6) CFU/g for Fort Beaufort, 1.6 x 10(3) and 1.6 x 10(5) CFU/g for Mdantsane, and 1.3 x 10(3) and 4.1 x 10(4) CFU/g for Alice. Four (10.3%) of 39 vegetable samples were confirmed to carry E. coli O157:H7. Four representative E. coli O157:H7 isolates from these vegetables were susceptible to at least one of the eight antimicrobial agents tested against them. Even though the prevalence of E. coli O157:H7 was low and those isolated were susceptible to most of the antimicrobials, there remains a need for E. coli O157:H7 surveillance in vegetables used in salad recipes in urban and rural areas of South Africa.